Grey zone lymphoma - diagnostic and therapeutic challenge

Danijela Agić, Tanja Lakic, Z. Nikin
{"title":"Grey zone lymphoma - diagnostic and therapeutic challenge","authors":"Danijela Agić, Tanja Lakic, Z. Nikin","doi":"10.2298/mpns22s1101a","DOIUrl":null,"url":null,"abstract":"Introduction. ?Grey zone Lymphoma?? is associated with various entities. The last published classification of lymphoproliferative neoplasms includes mediastinal grey zone lymphoma. Precise diagnostic criteria are insufficient and establishing a diagnosis is as complex as deciding on treatment options. In this article pathologist and hematologist discuss issues on this topic through case presentation and literature review. Clinical characteristics. It presents in the younger population usually with a mediastinal mass, sometimes large, with compressive symptoms. Pathologic characteristics. Some cases can?t be classified neither as Hodgkin nor Primary mediastinal B-cell lymphoma. Morphology resembles Hodgkin, but with a positive immunophenotype for primary mediastinal or diffuse large B-cell lymphoma, and vice versa. Case report. We presented a case of a 33-year-old male with cervical lymphadenomegaly, B symptoms and clinical deterioration during the diagnostic period. After the first biopsy, differential diagnosis was Epstein-Barr virus-associated lymphoproliferative disorder or classical Hodgkin lymphoma. The second biopsy confirms Epstein-Barr virus-positive diffuse large B-cell lymphoma. The World Health Organization Classification of lymphoproliferative neoplasms - clinical perspective. The term ?grey zone lymphoma? is associated with overlapping diagnosis or uncertainty in diagnosis in more clinical settings than the ones provided in the 5th World Health Organization Classification. Discussion. For now, chemotherapeutic regimen (rituximab-cyclophos phamide, doxorubicin, vincristine, prednisone) stays the standard first line therapy for diffuse large B-cell lymphoma regardless of the Epstein- Barr virus status. Mediastinal grey zone lymphoma treatment varies: chemotherapeutic regimen (rituximab-cyclophos phamide, doxorubicin, vincristine, prednisone) was linked with better outcomes than chemotherapeutic regimen (adriablastin, bleomycin, vinblastine, dacarbazine) +/-R, but for some patients chemotherapeutic regimen (dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) might be beneficial. Conclusion. Grey zone lymphoma is a rare hematologic malignancy that needs extensive sampling for correct diagnosis and is still subject to inter-observer variability.","PeriodicalId":87940,"journal":{"name":"Calcutta medical review","volume":"299 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Calcutta medical review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/mpns22s1101a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. ?Grey zone Lymphoma?? is associated with various entities. The last published classification of lymphoproliferative neoplasms includes mediastinal grey zone lymphoma. Precise diagnostic criteria are insufficient and establishing a diagnosis is as complex as deciding on treatment options. In this article pathologist and hematologist discuss issues on this topic through case presentation and literature review. Clinical characteristics. It presents in the younger population usually with a mediastinal mass, sometimes large, with compressive symptoms. Pathologic characteristics. Some cases can?t be classified neither as Hodgkin nor Primary mediastinal B-cell lymphoma. Morphology resembles Hodgkin, but with a positive immunophenotype for primary mediastinal or diffuse large B-cell lymphoma, and vice versa. Case report. We presented a case of a 33-year-old male with cervical lymphadenomegaly, B symptoms and clinical deterioration during the diagnostic period. After the first biopsy, differential diagnosis was Epstein-Barr virus-associated lymphoproliferative disorder or classical Hodgkin lymphoma. The second biopsy confirms Epstein-Barr virus-positive diffuse large B-cell lymphoma. The World Health Organization Classification of lymphoproliferative neoplasms - clinical perspective. The term ?grey zone lymphoma? is associated with overlapping diagnosis or uncertainty in diagnosis in more clinical settings than the ones provided in the 5th World Health Organization Classification. Discussion. For now, chemotherapeutic regimen (rituximab-cyclophos phamide, doxorubicin, vincristine, prednisone) stays the standard first line therapy for diffuse large B-cell lymphoma regardless of the Epstein- Barr virus status. Mediastinal grey zone lymphoma treatment varies: chemotherapeutic regimen (rituximab-cyclophos phamide, doxorubicin, vincristine, prednisone) was linked with better outcomes than chemotherapeutic regimen (adriablastin, bleomycin, vinblastine, dacarbazine) +/-R, but for some patients chemotherapeutic regimen (dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) might be beneficial. Conclusion. Grey zone lymphoma is a rare hematologic malignancy that needs extensive sampling for correct diagnosis and is still subject to inter-observer variability.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
灰色地带淋巴瘤——诊断和治疗的挑战
介绍。灰色地带淋巴瘤?与各种实体相关联。最近发表的淋巴增生性肿瘤分类包括纵隔灰色区淋巴瘤。精确的诊断标准是不够的,建立诊断和决定治疗方案一样复杂。在这篇文章中,病理学家和血液学家通过病例报告和文献回顾来讨论这个话题。临床特点。它在年轻人群中表现为纵隔肿块,有时较大,有压迫症状。病理特点。有些情况下可以?既不能归类为霍奇金淋巴瘤,也不能归类为原发性纵隔b细胞淋巴瘤。形态学类似霍奇金淋巴瘤,但原发性纵隔或弥漫性大b细胞淋巴瘤免疫表型阳性,反之亦然。病例报告。我们报告了一例33岁男性,在诊断期间出现颈部淋巴结肿大,B型症状和临床恶化。第一次活检后,鉴别诊断为爱泼斯坦-巴尔病毒相关淋巴细胞增生性疾病或经典霍奇金淋巴瘤。第二次活检证实eb病毒阳性弥漫性大b细胞淋巴瘤。世界卫生组织淋巴增生性肿瘤分类-临床观点。“灰色地带淋巴瘤”这个术语?与世界卫生组织第五次分类中提供的诊断相比,在更多的临床环境中与重叠诊断或诊断不确定有关。讨论。目前,化疗方案(利妥昔单抗-环磷酰胺、阿霉素、长春新碱、强的松)仍然是弥漫性大b细胞淋巴瘤的标准一线治疗方案,无论爱泼斯坦-巴尔病毒是否存在。纵隔灰色地带淋巴瘤的治疗方法各不相同:化疗方案(利妥昔单抗-环磷酰胺、阿霉素、长春新碱、泼尼松)的预后优于化疗方案(阿德里亚布拉西丁、博来霉素、长春新碱、达卡巴嗪)+/-R,但对某些患者而言,化疗方案(剂量调整-依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素)可能有益。结论。灰色地带淋巴瘤是一种罕见的血液恶性肿瘤,需要广泛的采样才能正确诊断,并且仍然受到观察者之间的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Drug development accelerated by artificial intelligence The artificial intelligence pharma era after “Chat Generative Pre-trained Transformer” Artificial Intelligence-enabled contactless sensing for medical diagnosis Cold-chain transmission, asymptomatic infection, mass screening, vaccine, and modelling: what we know so far for coronavirus disease 2019 control and experience in China A review on COVID-19 transmission, epidemiological features, prevention and vaccination
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1